SPOTLIGHT -
Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.
FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection
FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer
Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer
Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer
Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer
State of Science Summit- Breast Cancer: Chaired by Jennifer M. Matro, MD
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making